rAAVen Therapeutics wants to help pave the way for the next generation of gene therapies. The company uses cloning, virus variant production and sequencing to build novel viral vectors for precision targeting of defined cell populations or with desired properties.
Prior to founding rAAVen Therapeutics, Marcus spent the last decade on DNA barcoding and AAV engineering. Marcus started his work at Lund University, where he developed novel DNA barcoding methods for AAV engineering and gene therapy. Beside this, he has also worked extensively on generating DNA libraries, how to sequence DNA libraries and enhancer-promoter optimization.
He holds a PhD in Neuroscience from Lund University and has postdoc experience from Michigan State University in Grand Rapids, MI and Barrow Neurological Institute in Phoenix, AZ. Marcus is also a co-founder of BRAVE Bioscience.